Point72
VC Fund
Stamford, United States
Point72 is a VC fund in Stamford focused on Biotechnology and Pharmaceutical. Point72 invests in multiple asset classes and strategies worldwide.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 20%
- Fund size:
- $600M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Point72 invests in
Stages Point72 invests in
Countries Point72 invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anup Chamrajnagar
|
|||
Philip Farese
|
|||
Steven Cohen
|
|||
Deirdre Alphenaar
|
|||
Joel Barron
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 13 (33%)
- Pharmaceutical 6 (15%)
- Therapeutics 5 (13%)
- Health Care 4 (10%)
- FinTech 3 (8%)
Stage
- Post-IPO Equity 5 (13%)
- Series B 4 (10%)
- Series C 4 (10%)
- Series A 2 (5%)
- Seed 1 (3%)
Country
- United States 16 (40%)
- Canada 1 (3%)
- Israel 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anup Chamrajnagar
Ventures Investor
|
Ventures Investor | Total investments: 0 | Find email | |
|
Philip Farese
Senior Researcher
|
Senior Researcher | Total investments: 0 | Find email | |
|
Steven Cohen
Chairman, Chief Executive Officer, and Co-Chief Investment Officer
|
Chairman, Chief Executive Officer, and Co-Chief Investment Officer | Total investments: 13 | Find email | |
|
Deirdre Alphenaar
Head of Market Intelligence Integration
|
Head of Market Intelligence Integration | Total investments: 0 | Find email | |
|
Joel Barron
Head of Product Design
|
Head of Product Design | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SiFive
|
SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and moreaffordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small. | $400M / Series G / Apr 09, 2026 | |
Rivet Industries
|
Rivet Industries delivers front line hardware and software to the world's most important workers. | $57.5M / Series A / Mar 31, 2026 | |
Ovid Therapeutics
|
Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M / Post-IPO Equity / Mar 17, 2026 | |
Nscale
|
Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $2B / Series C / Mar 09, 2026 | |
Adlai Nortye
|
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $140M / Post-IPO Equity / Feb 03, 2026 | |
TONIX PHARMACEUTICALS HOLDING CORP.
|
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of the central nervous system (CNS) and immunology product candidates. The CNS portfolio includes bothsmall molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. | $20M / Post-IPO Equity / Dec 29, 2025 | |
X-energy
|
X-Energy is a nuclear reactor and fuel design engineering company that develops Generation IV, high-temperature gas-cooled small modular reactors (SMRs) together with proprietary TRISO-X particle fuel. Their flagship reactor, the Xe-100, delivers about 80 MWe per unit and can be scaled in modular “packs” to reach higher output. X-Energy also buildsits own TRISO-X fuel to maintain supply control and quality. In addition, the company operates a plant support center to provide fleet monitoring, maintenance planning, training, and diagnostics for its reactor customers. | $700M / Series D / Nov 24, 2025 | |
Cybin
|
Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $175M / Post-IPO Equity / Oct 28, 2025 | |
|
Nscale
|
Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $433M / Series C / Oct 01, 2025 | |
|
Nscale
|
Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $1.1B / Series B / Sep 25, 2025 | |
| See all 40 investments → | |||
Co-Investors
Eventide
6 deals together
Fidelity
6 deals together
Cowen Healthcare Investments
5 deals together
Adage Capital Management
4 deals together
NVIDIA
4 deals together
OrbiMed
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Point72 invest in?
Point72 invests primarily in Biotechnology, Pharmaceutical and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Point72?
Public channels for Point72 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Point72?
The team at Point72 includes Anup Chamrajnagar (Ventures Investor), Philip Farese (Senior Researcher) and Steven Cohen (Chairman, Chief Executive Officer, and Co-Chief Investment Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
